Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Boris Freidlin

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Statistics in Medicine|November 4, 2014
Assessing treatment benefit with competing risks not affected by the randomized treatmentEdward L Korn, James J Dignam, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2026
Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and SafetyBoris Freidlin, Edward L Korn, Robert G Maki
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2024
Phase III Evaluation of Treatment Combinations in Three-Arm TrialsEdward L Korn, Carmen J Allegra, Boris Freidlin
Human Heredity|August 22, 2003
Efficiency robust tests for mapping quantitative trait loci using extremely discordant sib pairsBoris Freidlin, Gang Zheng, Zhaohai Li, et al.
JCO Precision Oncology|September 14, 2020
Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker EvaluationMei-Yin C Polley, Edward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III clinical trials that integrate treatment and biomarker evaluationBoris Freidlin, Zhuoxin Sun, Robert Gray, et al.
ESMO Open|October 30, 2020
Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activityJared Foster, Boris Freidlin, E L Korn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2023
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)Yixuan Zhao, Ying Yuan, Edward L Korn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Reply to S. Goteti et alBoris Freidlin, Zhuoxin Sun, Robert Gray, et al.
Biometrics|March 2, 2005
Genomic control for association studies under various genetic modelsGang Zheng, Boris Freidlin, Zhaohai Li, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Statistics in Medicine|November 4, 2014
Assessing treatment benefit with competing risks not affected by the randomized treatmentEdward L Korn, James J Dignam, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 14, 2026
Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and SafetyBoris Freidlin, Edward L Korn, Robert G Maki
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2024
Phase III Evaluation of Treatment Combinations in Three-Arm TrialsEdward L Korn, Carmen J Allegra, Boris Freidlin
Human Heredity|August 22, 2003
Efficiency robust tests for mapping quantitative trait loci using extremely discordant sib pairsBoris Freidlin, Gang Zheng, Zhaohai Li, et al.
JCO Precision Oncology|September 14, 2020
Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker EvaluationMei-Yin C Polley, Edward L Korn, Boris Freidlin
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III clinical trials that integrate treatment and biomarker evaluationBoris Freidlin, Zhuoxin Sun, Robert Gray, et al.
ESMO Open|October 30, 2020
Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activityJared Foster, Boris Freidlin, E L Korn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2023
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)Yixuan Zhao, Ying Yuan, Edward L Korn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Reply to S. Goteti et alBoris Freidlin, Zhuoxin Sun, Robert Gray, et al.
Biometrics|March 2, 2005
Genomic control for association studies under various genetic modelsGang Zheng, Boris Freidlin, Zhaohai Li, et al.
Pageof 12